FDA Alerts

<p>The U.S. Food and Drug Administration has approved the use of opioid painkiller OxyContin in patients aged 11 to 16 who have not benefited enough from alternatives.</p>

The FDA has approved a new balloon device for the treatment of obesity without invasive surgery.

This FDA Roundup includes an at-a-glance look at the latest FDA drug approvals in June and July, including the first over-the-counter, nonprescription daily oral contraceptive, the first monoclonal...

The FDA has approved new options for basal cell carcinoma, HIV diagnosis, and high cholesterol that clinicians should be aware of.

The FDA has approved new options for major depressive disorder, schizophrenia, and metastatic non-small cell lung cancer, that clinicians should be aware of.

The FDA has decided to strengthen existing cardiovascular warnings on the labels of prescription non-aspirin nonsteroidal anti-inflammatory drugs.

The FDA has approved new options for the treatment of heart failure and cystic fibrosis, and issued a warning on unapproved prescription ear drops.

The FDA finalized a decision determining that partially hydrogenated oils were not generally recognized as safe.

...

An FDA advisory committee has voted to recommend approval of a new drug for the long-term treatment of patients with hypercholesterolemia and dyslipidemia.